Evidence map›Paper›PMID 36071824›Full record

ArticlePharmacogenomics and personalized medicine2022

Risk Factors and Predictive Model for Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease.

Kai Wang, Yian Tian, Shanshan Liu, Zhongyuan Zhang, Leilei Shen, Deqian Meng, Ju Li

Open access · goldAbstract read
In one paragraph

Article in Pharmacogenomics and personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: The CRAFT Model.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kai WangDepartment of Rheumatology, the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223001, People's Republic of China.ORCID 0000-0002-0511-8038
Yian TianDepartment of Rheumatology, the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223001, People's Republic of China.
Shanshan LiuDepartment of Rheumatology, the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223001, People's Republic of China.ORCID 0000-0002-2874-2845
Zhongyuan ZhangDepartment of Rheumatology, the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223001, People's Republic of China.
Leilei ShenDepartment of Rheumatology, the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223001, People's Republic of China.
Deqian MengDepartment of Rheumatology, the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223001, People's Republic of China.
Ju LiDepartment of Rheumatology, the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223001, People's Republic of China.
Huaian First People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Rapidly progressive interstitial lung disease (RP-ILD) is a significant complication that determines the prognosis of dermatomyositis (DM). Early RP-ILD diagnosis can improve screening and diagnostic efficiency and provide meaningful guidance to carry out early and aggressive treatment. Methods: A retrospective screening of 284 patients with DM was performed. Clinical and laboratory characteristics of the patients were recorded. The risk factors of RP-ILD in DM patients were screened by logistic regression (LR) and machine learning methods, and the prediction models of RP-ILD were developed by machine learning methods, namely least absolute shrinkage and selection operator (LASSO), random forest (RF), and extreme gradient boosting (XGBoost). Results: According to the result of univariate LR, disease duration is a protective factor for RP-ILD, and ESR, CRP, anti-Ro-52 antibody and anti-MDA5 antibody are risk factors for RP-ILD. The top 10 important variables of the 3 machine learning models were intersected to obtain common important variables, and there were 5 common important variables, namely disease duration, LDH, CRP, anti-Ro-52 antibody and anti-MDA5 antibody. The AUC of LASSO, RF and XGBoost test set were 0.661, 0.667 and 0.867, respectively. We further validated the performance of these three models on validation set, and the results showed that, the AUC of LASSO, RF and XGBoost were 0.764, 0.727 and 0.909, respectively. Based on the results of the models, XGBoost is the optimal model in this study. Conclusion: Disease duration, LDH, CRP, anti-Ro-52 antibody and anti-MDA5 antibody are vital risk factors for RP-ILD in DM. The prediction model constructed using XGBoost can be used for risk identification and early intervention in DM patients with RP-ILD and practical application.

Indexed as

dermatomyositisextreme gradient boostinginterstitial lung diseaseleast absolute shrinkage and selection operatorlogistic regressionpredictive modelrandom forestrisk factor

Identifiers

PMID36071824
PMCPMC9444234
OpenAlexW4294990949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.